Code of Federal Regulations: Containing a Codification of Documents of General Applicability and Future Effect as of December 31, 1948, with Ancillaries and IndexDivision of the Federal Register, the National Archives, 1998 Special edition of the Federal Register, containing a codification of documents of general applicability and future effect ... with ancillaries. |
No grāmatas satura
6.–10. rezultāts no 100.
42. lappuse
... procedures governing the use of in- vestigational new drugs set forth in part 312 of this chapter . ( d ) Any OTC daytime sedative drug product introduced into interstate commerce after December 24 , 1979 , that is not in compliance ...
... procedures governing the use of in- vestigational new drugs set forth in part 312 of this chapter . ( d ) Any OTC daytime sedative drug product introduced into interstate commerce after December 24 , 1979 , that is not in compliance ...
43. lappuse
... procedures governing the use of in- vestigational new drugs set forth in part 312 of this chapter . ( d ) After January 8 , 1990 , any such OTC drug product initially introduced or initially delivered for introduction into interstate ...
... procedures governing the use of in- vestigational new drugs set forth in part 312 of this chapter . ( d ) After January 8 , 1990 , any such OTC drug product initially introduced or initially delivered for introduction into interstate ...
44. lappuse
... procedures governing the use of in- vestigational new drugs set forth in part 312 of this chapter . ( d ) After March 9 , 1994 , any such OTC drug product initially introduced or initially delivered for introduction into interstate ...
... procedures governing the use of in- vestigational new drugs set forth in part 312 of this chapter . ( d ) After March 9 , 1994 , any such OTC drug product initially introduced or initially delivered for introduction into interstate ...
46. lappuse
... procedures governing the use of investigational new drugs set forth in part 312 of this chapter . ( d ) After the effective date of the final regulation , any such OTC cough- cold drug product that is labeled , rep- resented , or ...
... procedures governing the use of investigational new drugs set forth in part 312 of this chapter . ( d ) After the effective date of the final regulation , any such OTC cough- cold drug product that is labeled , rep- resented , or ...
47. lappuse
... procedures governing the use of investigational new drugs set forth in part 312 of this chapter . ( d ) After the effective date of the final regulation , any OTC drug product that is labeled , represented , or pro- moted for use as an ...
... procedures governing the use of investigational new drugs set forth in part 312 of this chapter . ( d ) After the effective date of the final regulation , any OTC drug product that is labeled , represented , or pro- moted for use as an ...
Saturs
279 | |
285 | |
290 | |
299 | |
310 | |
331 | |
339 | |
340 | |
223 | |
236 | |
238 | |
239 | |
240 | |
256 | |
257 | |
262 | |
263 | |
265 | |
270 | |
275 | |
351 | |
483 | |
588 | |
593 | |
696 | |
699 | |
761 | |
826 | |
865 | |
890 | |
911 | |
949 | |
Citi izdevumi - Skatīt visu
Bieži izmantoti vārdi un frāzes
abbre abbreviated application abbreviated new drug acid active ingredient adverse drug experience agency amended antibiotic application or abbreviated bacitracin bioavailability bioequivalence cation Center for Drug certification chapter clinical hold clinical investigation conducted control number copy Cosmetic Act digoxin dosage form dose Drug Administration drug application Drug Evaluation drug prod drug product Drug products containing drug substance Evaluation and Research Federal Food Food and Drug graph gredients hearing hydrochloride identified information requirements ap insulin intended inves investigational new drug labeling manufacturer marketing meet ment milligrams milliliters misbranded neomycin notice oral dosage orphan drug OTC drug product package paragraph percent person plication polymyxin proposed protocol recognized as safe reference listed drug request safe and effective safety section 502 Sodium sponsor statement submission Subpart sulfate tained tigational tion tive treatment treatment IND vestigational viated warning